The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from ...

Novo Nordisk shares rose Wednesday after fourth-quarter earnings beat Wall Street's estimates, 2025 forecast came in line ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

Ozempic and similar drugs are popular with consumers for their weight-loss properties, but a new study suggests they could ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Symptoms of NAION can include blurred vision, peripheral vision loss, dark spots in vision, and changes in color perception. Though the exact mechanism is not fully understood, researchers hypothesize ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

Novo Nordisk shares rose Wednesday after fourth ... behind Eli Lilly & Co. Details about its next-generation weight loss drugs CagriSema and amycretin are also in focus. It's been a rocky few ...